CENTER VALLEY, Pa.,
July 27, 2021 /PRNewswire/
-- Olympus Corporation today announced the launch of SeleCT
Connect™, a new program offering of its
SeleCT™ Quantitative Computer Tomography (QCT) analysis
service available immediately to more than 9,000 healthcare
facilities in the U.S. through the Nuance AI Marketplace, a
workflow-integrated cloud platform for diagnostic imaging AI
algorithms. The SeleCT QCT service will streamline and
optimize the screening process used to identify which patients are
eligible candidates to receive a treatment with the Spiration Valve
System, an FDA- designated breakthrough device for treating COPD
patients. The patient selection process involves a
thorough patient evaluation, including comorbidities, and
high-resolution CT (computed tomography) scan
analysis.4
The SeleCT Connect program is a collaboration between Imbio,
Olympus' partner for the AI-based SeleCT analysis, and Nuance
Communications, a leading provider of diagnostic
imaging, conversational AI, and ambient intelligence solutions
with a nationwide network of connected healthcare facilities.
SeleCT Connect provides treating physicians and radiologists
with an automated solution for sending CT studies directly from
their Picture Archive and Communication System (PACS) to the SeleCT
QCT analysis service; the SeleCT results are then automatically
returned to the patient record in the PACS following analysis. The
new service will also provide an option for SeleCT analysis results
to be sent to a health system's electronic health record (EHR) for
easier referring physician access.
"The connection to Nuance's expansive network of healthcare
facilities helps physicians to quickly and easily identify
qualified patients for key interventional respiratory procedures,"
said Lynn Ray, Global General
Manager and Vice President, Respiratory for Olympus. "Using
automated workflows, this solution enables treating physicians'
access to detailed diagnostic data from the Imbio AI imaging
solutions to determine if COPD patients can take advantage of our
breakthrough Spiration Valve therapy, which has been shown to
improve quality of life for qualified patients."1
"Our collaboration with Nuance and Olympus advances our mission
to add value and help deliver better patient care," said
Dave Hannes, CEO, Imbio. "Imbio
technology provides quantitative and personalized imaging analysis
to ensure accurate patient selection for Olympus' breakthrough
therapies using minimally invasive techniques, while the expansive
Nuance network extends access to precision therapies to thousands
of healthcare facilities across the
United States."
"Nuance's cloud-based diagnostic imaging network is supported by
AI-powered technology and services that aggregate and deliver
diagnostic intelligence from screening through follow-up," said
Peter Durlach, Chief Strategy
Officer at Nuance Communications. "Our work with Imbio and Olympus
is at the forefront of a rapidly expanding industry collaboration
with providers, payers, medtech and pharma businesses to apply the
power of diagnostic imaging at scale to meaningfully improve
patient outcomes, increase access to advanced therapies and reduce
costs."
For more information on SeleCT Connect or to start using the
service, Spiration Valve System customers can contact their Olympus
representative. For all new customers, click here to learn
more.
About SeleCT
Olympus offers the SeleCT™ QCT analysis
service to evaluate patient eligibility for treatment with the
Spiration® Valve System, an FDA-designated breakthrough
device to treat severe emphysema, a form of chronic obstructive
pulmonary disease (COPD). The SeleCT QCT analysis service analyzes
previously-taken CT images to quantify important measures of
emphysema, including emphysema distribution (heterogeneity), the
severity of lung tissue destruction and fissure integrity between
the lobes of the lung (which has been shown to be a surrogate for
collateral ventilation). Advancing the field of QCT analysis
is a critical goal for Olympus as it builds on physician, patient,
and healthcare system goals for less-invasive diagnostic and
therapeutic options, and it leverages the undisputed expertise and
leadership Olympus has developed over the last 13 years in the
field of bronchoscopic lung volume reduction (BLVR) therapy.
About Olympus
Olympus is passionate about the
solutions it creates for the medical, life sciences, and industrial
equipment industries.
Olympus' Medical business uses innovative capabilities in
medical technology, therapeutic intervention, and precision
manufacturing to help healthcare professionals deliver diagnostic,
therapeutic, and minimally invasive procedures to improve clinical
outcomes, reduce overall costs, and enhance the quality of life for
patients. Olympus' Medical portfolio includes endoscopes,
laparoscopes, and video imaging systems, as well as surgical energy
devices, system integration solutions, medical services, and a wide
range of endotherapy instruments. For more information, visit
https://medical.olympusamerica.com/.
About Imbio
Imbio is a leader in fully-automated AI
image analysis for acute and chronic pulmonary and cardiothoracic
conditions. Imbio's solutions transform the way patients are
discovered, diagnosed and treated, enabling physician productivity
and more personalized care for patients. Imbio's solutions are
fully automated, regulatory cleared and available through our
global partners. For more information, please visit
www.imbio.com.
About Nuance Communications
Nuance Communications
(NASDAQ: NUAN) is a technology pioneer with market leadership in
conversational AI and ambient intelligence. A full-service partner
trusted by 77 percent of U.S. hospitals and 85 percent of the
Fortune 100 companies worldwide, Nuance creates intuitive solutions
that amplify people's ability to help others.
Trademark reference: Nuance and the Nuance logo are
registered trademarks or trademarks of Nuance Communications, Inc.
or its affiliates in the United
States and/or other countries. All other trademarks
referenced herein are the property of their respective
owners.
1 Am J Respir Crit Care Med. 2019 Dec 1;200(11):1354-1362. doi:
10.1164/rccm.201902-0383OC.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/olympus-makes-select-qct-analysis-available-nationwide-via-the-nuance-ai-marketplace-to-increase-access-to-spiration-valve-system-therapy-301342002.html
SOURCE Olympus Medical Systems Group